Infusion therapy is a lifeline for people living with autoimmune disorders and chronic conditions. It’s also frequently ...

There were 11 hypersensitivity reactions, all in patients receiving nivolumab. Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival. HealthDay News — For patients with extensive-stage small cell ...